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Abstract
Background and purpose: Target point identification based solely on MRI and CT of subthalamic nucleus (STN)
in deep brain stimulation procedures (DBS) for Parkinson’s disease (PD) might have suboptimal clinical effects. The
authors analyse alterations of permanent electrode location depending on neurophysiological evaluation compared
to an anatomically based calculated target.
Materials and methods: The group comprised 66 patients (32 females and 34 males) aged 57.6 (38–76) years,
in whom 131 electrodes were implanted. The patients were qualified for the surgery according to the CAPSIT-PD
criteria. STN was identified using the direct and indirect methods, based on 1.5 T MRI and CT. The surgery was
performed under local anesthesia. Two to 5 microelectrodes were used for microrecording and macrostimulation.
Results: Anterior (49.2%), central (35.6%) and lateral (13.6%) trajectories were most frequently used for
permanent electrode placement. The electrode was most frequently placed at a depth of +2/+3 (58.3%) or +1 and
+5 mm (36.4%) with regard to the planned target point. Differences in selecting the trajectory and depth of the final
electrode position were statistically significant (p<0.05).
Conclusion: DBS implantation based only on anatomical identification of STN can lead to suboptimal results.
Additional application of intrasurgical neurophysiological analysis may increase the effectiveness of the STN DBS
therapy for PD.
Keywords: Microrecording; Macrostimulation; Parkinson’s disease;
Deep brain stimulation; Subthalamic nucleus
Introduction
Parkinson’s disease (PD) is a cause of disability in 1.5% of the
population aged over 60 years of age and is an important socio-
economic problem. So far, no specific treatment for this
neurodegenerative process is available. Symptomatic treatment of PD
consists mainly of pharmacological supplementation and modulation
of the dopaminergic system.
In 4–10% of patients with PD, insufficient pharmacological
treatment may force a neurosurgical treatment trial. Neurosurgical
ablative treatment (pallidotomy, thalamotomy) of PD was introduced
in the 1940s and was effective in selected patients. However, the risk of
irreversible neurological deficits after the surgery was the main cause
of progress of functional neurosurgery at the time of the introduction
of L-dopa for the treatment of PD.
A breakthrough in the neurosurgical treatment of movement
disorders was the introduction of modern systems for deep brain
stimulation (DBS) in the 1980s. DBS has similar efficacy to that
observed after ablative surgery, with far less risk of permanent
complications. A milestone for the understanding and treatment of PD
was the development in 1976 of a laboratory model of dopaminergic
system disorders and identification of the optimal surgery target for
the treatment of major PD symptoms in the subthalamic nucleus
(STN). Due to the occurrence of serious side-effects after surgical
ablation of the subthalamic nucleus (hemibalismus), only a few centres
had used this target before the introduction of DBS surgery [1-5].
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The introduction of modern techniques of neuroimaging, including
MRI, allowed very precise identification of brain structures, including
the STN [6-18], in a minimally invasive manner. However, the
anatomic identification of STN by MRI may not correspond to its
neurophysiological activity, thus hindering achievement of the
optimum therapeutic effect [19-26].
Patients
The study group comprised 66 consecutive patients (32 women and
34 men) who underwent implantation of a 131 STN DBS system
because of PD. Microrecordings were conducted with 462 trajectories.
Age at surgery was on average 57.6 (38–76) years and disease
duration was on average 10 (6–21) years. Patients were qualified for
surgery based on the criteria contained in CAPSIT-PD [27-30]. The
qualification process was performed in reference centers involved in
the treatment of neurological diseases. The patients who qualified for
the surgery were in stages II-IV disease according to the Hoehn-Yahr
scale, with a mean daily demand for L-dopa of 1100 mg (95% CI: 938–
1262). The mean UPDRS III was 49.2 (95% CI: 45.5–52.8) in the OFF
and 20.9 (18.3–23.8) in the ON phase (Table 1).
 Mean (95% CI) Median (Range)
Age [yrs] 57.6 (55,7-59,5) 58 (38-76)
UPDRS III before DBS   
- OFF phase 49.2 (45,6-52,8) 48 (15-77)
- ON phase 20.9 (18,3-23,8) 19 (7-53)
- (OFF-ON)/OFF ratio (%) 52.0% (47,7-56,4) 54.4% (21,3-8,4)
Active DBS treatment   
- ON phase 9.8 (7,9-12,2) 8 (2-47)
Improvement after DBS † 46.3% (40,4-52,1) 49.2% (9,1-90,0)
Table 1: Demographic data († Calculated according to the equation (III
UPDRS score in ON phase before DBS treatment minus III UPDRS
score in ON phase with DBS)/III UPDRS score in ON phase before
DBS treatment).
Surgery and neurophysiological studies
All patients underwent 1.5 T MRI. Scans were performed using the
following protocol: T2 axial 1.5 mm/slice gap 0.2, T1 contrast axial +
1.5 mm/slice gap 0.2. Pharmacological treatment was discontinued at
least 12 h before surgery. Patients did not receive anticoagulation for at
least 7 days before surgery except for low molecular weight heparin.
Procedures were carried out under local and general anesthesia. After a
CT with stereotactic frame acquisition (with contrast, every 1.5 mm,
no gantry tilt), MRI image fusion was performed (Framelink 5.3,
Medtronic).
The patient was then moved to the operating theatre. The indirect
method was used to identify the target point (mid. AC-PC: 11, -2, -4)
and directly by modifying the target depending on the MRI image
[7-18]. After determining the entry point using a stereotactic frame
(Leksell, Elekta), the burr hole was made around the coronal suture (3–
5 cm lateral to the midline) and a skull-fastening system was attached
to the micro- and macroelectrode positioning systems. During
macrostimulation the following clinical symptoms were assessed:
rigidity, bradykinesia, resting tremor and side-effects [31-34]. The
macrostimulation was supervised and conducted by a
neurophysiologist and neurologist or neurosurgeon trained in the
evaluation of extrapyramidal diseases. The microrecording and
macrostimulation have been archived.
Microelectrode recordings (MERs) of STN neuronal activity and
adjacent structures were carried out using a biological signal amplifier
and software devoted to recording and analysing extracellular
potentials generated by single neurons (Leadpoint®, Medtronic).
Extracellular recordings of spontaneous activity of neurons, the target
structure and neighbouring structures (thalamus, zona incerta,
substantia nigra), were performed for 2 to 5 trajectories (central,
anterior, medial, lateral and posterior). Before each recording,
electrode resistance was measured (minimum electrode resistance was
>1 kΩ) and potential sources of artifacts eliminated.
Electrophysiological activity was recorded from -10 mm to + 6 mm
from the target point. The bandwidth for recording was 3 Hz to 10
kHz. Spontaneous activity of neurons was recorded at intervals of 1
mm. The recording time was at least 30 s, 15 s after the end of
micromanipulator motion of the electrodes. The spontaneous activity
of the neurons was analysed visually and the average frequency of APs
of neurons located at the microelectrode was also analysed. STN
neurons were identified based on the following criteria: a two-fold
increase in the amplitude of background activity and irregular
discharges of action potentials in the frequency range of 30–60 Hz. The
reticular part of the substantia nigra (SNr) was identified as regular
discharges of APs with a frequency of 70–90 Hz, and the amplitude of
the background potentials were lower than in the STN. Each trajectory
was assessed based on the microrecording examination limits on the
STN. The trajectory that registered the best STN activity was chosen
for electrical stimulation to assess the effectiveness of the DBS. In the
case of unsatisfactory clinical efficacy or adverse reactions to low-
intensity stimulus (<3 mA), stimulation of STN was situated at points
within the next trajectory. Macrostimulation was performed using a
rectangular current stimulus with a duration of 60 μs supplied with a
frequency of 130 Hz in the current range, from 0 to 8 mA.
The current amplitude was increased by 1 mA to evaluate the
clinical effect of stimulation. If any side-effects occurred, the
stimulation current was not increased. If adverse reactions were
observed at low stimulus intensity (<3 mA), stimulation was initiated
in the next trajectory. The effect of stimulation was evaluated clinically
with the influence of the following symptoms: rigidity, bradykinesia
and tremor. The final locations for permanent implantation of
electrodes were selected based on the effectiveness of the stimulation
and the lack of side-effects. After identifying the optimal target for
stimulation, the stimulating electrode (Medtronic, 3389) was removed
and a permanent brain electrode was introduced under the control of a
fluoroscope. The electrode was attached to the bone using a latch
(Stimlock, Medtronic). After the closure of the wound, the stereotactic
frame was removed. After receiving antiparkinsonian medication the
patient was subjected to general anesthesia. After the liaison of wire
under the skin, the stimulator was introduced into the subcutaneous
tissue around the subclavian or abdominal wall. Control imaging
studies (CT) were performed within 24 h of surgery. The pacemaker
programming process took place 6 weeks after surgery. In two patients
the electrodes were implanted unilaterally; in the remaining cases,
bilaterally. In one patient, the stimulating system was removed and
reimplanted due to local infection.
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Statistical Analysis
Variables measured on a nominal or ordinal scale are presented in
percentages with a 95% confidence interval (95% CI). Normal
qualitative variables are presented both by the arithmetic mean of 95%
and the median with the range of values in cases of the non-Gaussian
distributions. The comparative analysis of qualitative variables
routinely used the chi-square test and, if the expected frequencies <5
exact two-sided, Fisher’s exact test. Quantitative variables at
subsequent time points were compared using the Wilcoxon test
sequence pairs. A level of p<0.05 was adopted for all tests of statistical
significance. Statistical calculations were performed using
STATISTICA 8.0 PL (StatSoft, 2008).
Results
In the initial period, cathodal stimulation on contacts (C +, 0-, 1-)
was applied with a frequency of 130 Hz, with a pulse width of 60 µs
and an amplitude of up to 1.0 V [35]. Then, depending on the
response, the parameters of stimulation were modified by introducing
bipolar stimulation and increasing the amplitude to 2.5 V. Controlled
clinical evaluations were carried out after 6 months in 50 (75.6%)
patients. Reductions in severity of the neurological syndrome
quantified by the UPDRS III were evaluated on average at 46.3% (9.1–
90%, p<0.001). The mean daily dose of L-dopa was 525 mg (95% CI:
347–704), which was a significant reduction of 48% as compared to the
state before DBS.
Among 66 patients treated with permanent 131 electrodes, the most
frequent final positioning trajectories, based on neurophysiological
assessment, were as follows: Anterior trajectories (49.2%), central
(35.6%) and lateral (13.6%).
The medial and posterior trajectories were chosen in individual
cases (Table 2). Differences in the incidence of choice of trajectories
were statistically significant (p<0.05) (Figure 1). The depths at which
electrodes were left permanently were in all cases different from what
had been planned preoperatively. The electrode was in most cases left
at a depth of 2 or 3 mm (58.3%), followed by 1 or 5 mm (36.4%) and 5
or 6 mm (5.3%) (Figure 2 and Table 2). Differences in frequency
between successive groups of depth were statistically significant
(p<0.05) (Figure 2).
Figure 1: Final placement of the stimulating electrode in respect to
planned in MRI target.
Figure 2: Percentages of trajectories of implanted electrodes
adjusted after MER.
 N=131 % (95%CI)
Final trajectory   
Medial 2 1,5% (0, 4-5, 4)
Lateral 18 13,6% (8, 8-20, 5)
Posterior 0 0,0% (0, 0-2, 8)
Central 47 35,6% (28, 0-44, 1)
Anterior 65 49,2% (40, 9-57, 7)
Final depth of electrode placement   
1+ mm 24 18,2% (12, 5-25, 6)
2+ mm 40 30,3% (23, 1-38, 6)
3+ mm 37 28,0% (21, 1-36, 2)
4+ mm 24 18,2% (12, 5-25, 6)
5+ mm 4 3,0% (1, 2-7, 5)
6+ mm 3 2,3% (0, 8-6, 5)
Table 2: Final trajectories and final electrode placement in respect to
planned in MRI target.
There was one infectious complication (1/131 implantation-0.76%),
which caused the removal of the system. After three months and the
end of antibiotic therapy, the system was effectively reimplanted. Four
patients (4/131 implantation-3%) had erosion of the skin over the
pacemaker or connector. No intracranial bleeding was reported at the
control CT scan in the presented group of 66 patients with implanted
131 DBS systems in which 462 MER trajectories were performed.
Discussion
In the 1940s, most authors were already using intraoperative
stimulation of the deep brain structures as a test for ‘reverse lesions’ to
identify certain structures (i.e., globus pallidus) during ablative
treatments. Intraoperative neurophysiological tests could predict the
therapeutic effect of ablative surgery. After turning on the stimulation,
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there was improvement in PD symptoms; once it was turned off,
symptoms recurred. Maintaining the intraoperative and perioperative
stimulation of selected cases improved the effectiveness and safety of
ablative procedures. The next natural step was the introduction of
permanent pacemakers for DBS [1-3].
In the last two decades functional neurosurgery has developed
rapidly, mainly due to the introduction of DBS. In different DBS
therapy centers, intraoperative neurophysiological evaluation and/or
neuroimaging planning is used to identify the target. Neuroimaging
methods of STN identification frequently use a high-pole MRI. Direct
target identification is based on high-resolution T2 scans. Indirect
identification is based on the location of the anterior and posterior
commissure, the nucleus rubber, mammillary bodies and the third
ventricle wall. According to some authors, an MRI is sufficient to
identify an STN, especially if it is carried out on a high-pole MRI.
However, most authors confirm the position of an STN
intraoperatively with neurophysiological studies, including the use of
microrecording, macrostimulation or both [8,9,13,14,17,19].
The role of neurophysiological evaluation
MER of neuronal activity has been proven effective in determining
the boundaries of a subthalamic nucleus. Analysis of the STN neuronal
activity is an important complement to the stereotactic planning of the
implantation target for a DBS electrode. MER allows for the evaluation
of the real-time activity of STN neurons. This allows the optimal target
for permanent electrode placement to be determined
neurophysiologically on the basis of trial macrostimulation along the
trajectories initially determined by MER [19,21,24,31-34].
In the present study it was found that the most effective clinically
permanent electrode trajectories were the anterior, central or lateral
trajectories. Stimulation along these trajectories was associated with
the largest reduction of Parkinsonian symptoms (with low currents
used and no side-effects) evaluated intraoperatively. These
observations were further confirmed after the implantation of a DBS
system. In long-term follow-up, the improvement in clinical status of
patients and the reduction of dopaminergic drugs dosage was about
50%, which is similar to previous reports [36-41].
The mechanism of neurostimulator action is not fully understood.
The essential idea of deep brain stimulation action is based on
inhibiting structures that are excessively active in the pathological
pathways of basal ganglia. The main mechanisms of DBS action are the
depolarisation blockade of neurons (the inactivation of sodium ion
channels), synaptic depolarisation inactivation, antidromal release of
GABA within the basal ganglia network, and activation of local
inhibitory mechanisms within the DBS target [6]. The most significant
feature of DBS treatment is the possibility of reversible and complete
inhibition of hyperactive structures. It is therefore logical and
reasonable to implant DBS electrodes in the parts of the target
structures that are the most hyperactive—the activity of which is to be
modulated. Because the neuroimaging determination of the target
point was similar in all patients, the profile of the trajectory chosen as
the permanent location of the electrodes (based on neurophysiological
evaluation) indicates that the most effective treatment seems to be the
stimulation of the anterolateral-area STN. These results are consistent
with the previously described clinical and anatomical data, according
to the previously described most optimal neurostimulation region,
which is the anterior dorso-lateral part of the STN (anterior dorsal-
lateral Forel axis of the forebrain) [36,37].
However, this area, although anatomically defined, is not
functionally uniform, and the optimal region for stimulation effects
can be in the front (the anterior trajectory) or side (the lateral
trajectory) of the STN. Determining the most effective and safe
location for DBS therapy is only possible using MERs and test
stimulations, which are the only tests that can determine the effects of
stimulation of certain parts of the STN in real time and in awake
patients. Determining the target based solely on morphological data,
even with a high-pole MRI, may not be compatible with a functionally
determined target for DBS [21-24,31-34]. Despite the fact that
neurophysiological research requires the cooperation of additional staff
and is time-consuming, these facts seem to confirm the efficacy of the
protocol.
The integrative approach in planning the final target for a DBS
electrode (morphological—neuronavigation, neurophysiological-
microrecording and functional—MER and intraoperative
macrostimulation) allows for the determination of the optimal target
for permanent implantation of electrodes. As shown by these results,
the final place of implantation of DBS electrodes in most cases was on
a different level—2 to 3 mm from the planned target, and only 35% of
the central trajectory. Optimising the position of the permanent
electrode is important for the following reasons: the choice of a target
in which the smallest stimulus intensity causes significant clinical effect
greatly extends the life of DBS electrodes. The target associated with
the lowest rate of side-effects significantly improves the quality of
permanent pacing.
DBS implantation is subject to a small risk of bleeding
complications, similar to that observed for other stereotactic surgery,
and ranges from 0.6 to 3.3%; the incidence of intracranial bleeding
producing clinical symptoms remained at >1% [32,42-50]. Most
authors recognise the use of several microelectrodes to be safe; there
was no correlation between the risk of bleeding and the number of
microelectrodes used [32,42,44-48]. In a retrospective analysis, Mikos
et al. described the incidence of bleeding complications up to 4.3%—
however, with the use of transventricular electrodes [43]. Hariz and
Fodstad drew attention to the increased risk of bleeding complications
when using a larger number of trajectories in their review paper [49],
but this review was also based on abstract communications and
chapters that were not subject to assessment by reviewers in the
process of publication [49]. The analysis, covering up to 644 patients
undergoing ablation or DBS, showed no correlation between the
number of trajectories and the risk of bleeding during DBS surgery
[44,47].
Conclusion
Our results indicate that target identification based on
morphological data in most cases is not identical with
neurophysiologically assessed targets for deep brain stimulation. There
is a risk of suboptimal effects during the implantation of a DBS system
based only on neuroimaging. Therefore, intraoperative
neurophysiological evaluation seems to be fully justified and should be
an integral part of the procedure, despite the increased length of
surgery and the need to engage additional staff (a neuroscientist and a
neurologist).
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